3689.Hk
3689.HK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
Business. 3689.HK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
3689.HK operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.
The company maintains a relatively strong liquidity position, with a current ratio of 1.35, indicating that it has sufficient current assets to cover its current liabilities. However, the company's liquidity is assessed as medium, and it is noted that net cash is negative after subtracting total debt, suggesting potential liquidity constraints.
In terms of profitability, the company's return on equity (ROE) is 6.6%, and its return on assets (ROA) is 3.72%. These figures are below the industry median for ROE and ROA, indicating that the company is underperforming its peers in terms of generating returns from equity and assets.
The company's capital structure is characterized by a debt-to-equity ratio of 0.22, which is relatively low, suggesting a conservative approach to financing. The company's long-term debt is 326,069,000 CNY, and its total equity is 1,509,233,000 CNY. The company's revenue is primarily derived from a single segment, and there is no significant geographic diversification reported.
The company's growth trajectory is not explicitly detailed in the available data, but its revenue for the latest period is 2,024,200,000 CNY. The outlook for the current and next fiscal years is not provided, but the company's historical revenue performance suggests a stable, albeit modest, growth rate.
The company's risk profile is marked by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. There are no significant dilution risks identified, and the company has not made any recent equity issuances that would suggest a high dilution potential.
There are no recent events or filings that have been disclosed in the available data. The company's financial statements do not indicate any significant changes in operations, management, or strategic direction that would impact its financial performance in the near term.
- The company has a conservative capital structure with a low debt-to-equity ratio.
- The company's liquidity is assessed as medium, with a current ratio of 1.35.
- The company's profitability, as measured by ROE and ROA, is below the industry median.
- The company's revenue is primarily derived from a single segment, indicating a lack of diversification.
- The company's risk profile is characterized by a medium liquidity risk and a low dilution risk.
- "margin_outlook_rationale": "The company's gross profit margin is expected to remain stable, driven by consistent pricing and cost management strategies.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Return On Assetsnet_income / total_assets
- 3689.HK Market data — financials · 2026-05-26
Ownership & reference
Leadership
- Junyang WangExecutive Chairman of the Board
- Wangzhi ChenChief Executive Officer, Executive Director